Evogene Ltd. Announces $2.9 Million At-The-Market Offering Agreement with A.G.P.

On June 11, 2026, Evogene Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an 'at the market' (ATM) offering. Under the terms of the agreement, the company may offer and sell its ordinary shares from time to time through the Agent for an aggregate offering price of up to $2,926,500. The shares will be issued pursuant to a previously filed shelf registration statement on Form F-3, which became effective on March 28, 2024. Evogene is not obligated to make any sales under the agreement and may terminate the arrangement at any time. The company will pay the Agent a cash commission of 3.0% of the gross proceeds from any shares sold. The proceeds are intended to support general corporate purposes. Evogene's ordinary shares are currently listed on the Nasdaq Stock Market under the symbol 'EVGN' and on the Tel Aviv Stock Market.